Navigation Links
New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
Date:5/23/2008

CHAPEL HILL, N.C., May 23 /PRNewswire/ -- With increased FDA scrutiny around new medicines and heightened competition from generics in the pharmaceutical market, marketing teams and science staff have to be even more delicate when communicating clinical trial results of new drugs in development. With less products making it through development, communications for the ones that do have to be spot on to favorably impact launch success. Marketers see coordination and timing activities as top challenges. One interviewed marketing executive states, "we have to worry about competitors stealing your thunder, but also worry about physicians forgetting what our trial was about."

According to a Best Practices, LLC benchmarking study, the marketing team creates preliminary communication plans to create a memorable identity linking study results to the product and to identify target audiences, key messages and effective activities for disseminating the study results long before the study even begins.

Planning and communication tactics along with other key strategies for optimizing the likelihood of a drug's market success are compiled in the benchmarking report, "From Breakthrough to Blockbuster: Best Practices in Communicating Clinical Trial Results."

Download the complimentary research summary of this benchmarking study including the table of contents, sample best practices and data charts at http://www3.best-in-class.com/rr948.htm.

The report presents the lessons learned and best practices gleaned from survey responses and interviews with pharmaceutical executives at world-class companies, including Abbott, AstraZeneca, Aventis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Schering-Plough and Wyeth. In the report, executives reflect upon the critical steps to communicating clinical trial results to diverse physician, managed care, investor and
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
2. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
5. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
6. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
7. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
8. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
9. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Boston Scientific Corporation (NYSE: ... to purchase the Interventional business of Bayer AG. ... to offer physicians and healthcare systems a more ... conditions. The addition of the Bayer ... the Boston Scientific strategy to provide a comprehensive ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on its ... device market, Frost & Sullivan recognizes Novian Health, ... Sullivan Award for Technology Innovation Leadership. Novian Health ... and malignant tumors with its proprietary technology, Novilase ... a reliable, accurate, and easy-to-control ultrasound-guided thermo ablation ...
(Date:9/2/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... consumables to the medical, research and veterinary markets, announced ... Executive Officer, will present at the Morgan Stanley Global ... a.m. ET. The conference will be held at the ... City . About Abaxis Abaxis develops, ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
... 1 Clinicians at Institut Catala d,Oncologia (ICO) in Barcelona ... RapidArc® radiotherapy from Varian Medical Systems (NYSE: VAR). A 73-year-old prostate cancer ... country to receive the fast and efficient treatment. , ... "The treatment went very well and the patient ...
... SAN DIEGO , June 1, 2010 Amylin Pharmaceuticals, ... , MD has been appointed Senior Vice President, Research and Development. ... Chief Medical Officer. These leadership changes will strengthen the Company,s focus ... its late-stage development programs, both important value drivers for the Company. ...
Cached Medicine Technology:Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 2Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 3Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 4Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 2Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 3Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 4Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development 5
(Date:9/2/2014)... September 02, 2014 Eric Jimenez and ... Me , a revolutionary makeup application device. Designed to ... proven innovation in the palm of women’s hands to ... secret to Color Me’s success lies in its patented ... a rate of 15,000 pulses per minute, the device ...
(Date:9/2/2014)... NJ (PRWEB) September 02, 2014 BESLER ... protection services for hospitals, is pleased to announce that ... in-depth review of the FY 2015 Hospital Inpatient ... the Centers for Medicare & Medicaid Services. , “Hospitals ... variety of reasons,” said Jonathan Besler, BESLER’s President and ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the world-famous ... Lee has the unique distinction of being the first and ... history, Misty Lee is the first female magician to hold ... staff Medium at the Magic Castle,” says Misty Lee. “Even ... being at the Magic Castle, I can fascinate guests in ...
(Date:9/2/2014)... Request A Test , a leading national provider of direct to ... drug testing in September 2014. To take advantage of ... when placing their order. Request A Test offers a variety ... is typically done in panels which screen for multiple types of ... the 5 Panel Urine Screening and 10 Panel ...
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
Breaking Medicine News(10 mins):Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Magician Misty Lee is the First and Only Female Staff Medium at Hollywood’s Magic Castle 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 2Health News:Request A Test Offers 10% Off Drug Testing in September 2014 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5
... who fear their own death say they are more prepared ... whom further medical treatment is considered futile,// reveals research published ... Archives of Disease in Childhood. ,The findings ... in the care of sick newborns (neonatologists) across Australia and ...
... low numbers of organ donors in Australia is an ongoing ... ,In the latest edition of the Medical Journal ... of the issues surrounding organ donation in Australia. ... the second the impact of public education campaigns on organ ...
... According to a latest Government data, there is an alarming ... this could be linked to the plummeting sale of// antidepressants. ... and Prevention (CDC) also indicated that youth in their late ... Food and Drug Administration had issued a black box warning ...
... using a sophisticated form of analysis called meta-analysis, in which ... for// possibly preventing up to half of the cases of ... in the United States. The work was conducted by a ... Center at University of California, San Diego (UCSD), and colleagues ...
... the United States and a growing epidemic worldwide. Now, ... able to make a valuable contribution to an overall ... ,A study published in the Journal of Vertebral ... when used as part of an integrative treatment in ...
... there is a pronounced increase of mental illnesses ... spectrum disorders, obsessive// compulsive disorders and hyperkinetic illnesses. ... Pediatric and Adolescent Medicine. ,Researches are ... to the increased awareness about these diseases or ...
Cached Medicine News:Health News:Doctors’ Own Fear of Death Linked to Hastening Death of Very Sick Newborn 2Health News:The Search for Organ Donors 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 3Health News:Research Explores Chiropractic's Effect on Diabetes 2
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Control is designed to monitor the performance of urine dipstick testing. The control is available in 12 mL ready-to-use dropper bottles....
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Medicine Products: